Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
Pharmanutra S.p.A
PHNPharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, Europe, the Middle East, South America, Far East, and internationally. It also produces and markets pharmaceuticals, medical devices, OTC products, and nutraceuticals for pediatric sector; and produces and distributes raw materials and active ingredients for the food, pharmaceutical, and food supplement industries. The company's products primarily include SiderAL, SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med, Cetilar Crema, Cetilar Patch, Cetilar Tape, Cetilar Oro, Cetilar Nutrition, ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2. It distributes and sells its products through sales representatives, wholesalers, pharmacies, and para-pharmacies. The company was founded in 2003 and is based in Pisa, Italy. Address: Via Campodavela 1, Pisa, PI, Italy, 56122
Analytics
Zielpreis von Wall Street
75.92 EURKGV
35.3642Dividendenrendite
1.53 %Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Schlüsselzahlen PHN
Dividenden-Analyse PHN
Dividendenwachstum über 5 Jahre
142 %Kontinuierliches Wachstum
4 JahreAusschüttungsquote 5-Jahres-Durchschnitt
40 %Verlauf der Dividende PHN
Bewertung der Aktie PHN
Finanzen PHN
Ergebnisse | 2019 | Dynamik |